Wilson Sonsini Goodrich & Rosati advised Cimeio Therapeutics on the transaction. Cimeio Therapeutics, an immunotherapy company, announced that it has entered a research collaboration with Kyowa...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Aytu BioPharma on the transaction. Aytu BioPharma, Inc. (the “Company” or “Aytu”) (Nasdaq:AYTU) and Lupin Pharma Canada Ltd (“Lupin”), a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Ripple on the transaction. Ripple Therapeutics Corporation (Ripple) announced a collaboration and option-to-license agreement with AbbVie to develop RTC-620, a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised BigHat on the transaction. AbbVie Inc. and BigHat Biosciences announced a research collaboration to discover and develop next-generation therapeutic antibodies...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati represented IVIVA in the transaction. United Therapeutics (Nasdaq:UTHR) announced it acquisition of all of the outstanding equity of IVIVA Medical, Inc., a...
You must be a Standard 1 Year member to access this content.
Wilson Sonsini Goodrich & Rosati advised Related Sciences on the transaction. Charles River Laboratories International, Inc. (NYSE:CRL) and Related Sciences announced a multi-program collaboration agreement to apply Logica™—an...
You must be a Standard 1 Year member to access this content.
